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ABSTRACT
Aims Since 2008, KRAS mutation status in exon 2 has
been used to predict response to anti-EGFR therapies.
Recent evidence has demonstrated that NRAS status is
also predictive of response. Several retrospective
‘extended RAS’ analyses have been performed on clinical
trial material. Despite this, are we really moving towards
such extended screening practice in reality?
Methods Data were analysed from four consecutive UK
National External Quality Assessment Service for
Molecular Genetics Colorectal cancer External Quality
Assessment schemes (during the period 2014–2016),
with up to 110 laboratories (worldwide) participating in
each scheme. Testing of four or ﬁve tumour samples is
required per scheme. Laboratories provided information
on which codons were routinely screened, and provided
genotyping and interpretation results for each sample.
Results At least 85% of laboratories routinely tested
KRAS codons 12, 13 and 61. Over the four schemes, an
increasing number of laboratories routinely tested KRAS
codons 59, 117 and 146. Furthermore, more
laboratories were introducing next generation sequencing
technologies. The pattern of ‘extended testing’ was
reassuringly similar for NRAS, although fewer
laboratories currently test for mutations in this gene.
Alarmingly, still only 36.1% and 24.1% of participating
laboratories met the ACP Molecular Pathology and
Diagnostics Group and American Society of Clinical
Oncology guidelines, respectively, for extended RAS
testing in the latest assessment.
Conclusions Despite recommendations in the UK and
USA on extended RAS testing, there has clearly been,
based on these results, a delay in implementation.
Inadequate testing results in patients being subjected to
harmful treatment regimens, which would not be the
case, were routine practice altered, in line with evidence-
based guidelines.
INTRODUCTION
Over the past few years, KRAS mutation testing has
become compulsory as a prerequisite for the treat-
ment of patients with metastatic colorectal cancer
(mCRC), with anti-EGFR monoclonal antibody
(mAb) therapies such as cetuximab or panitumu-
mab. It has been well established that patients with
mutations in exon 2 (codons 12 and 13) of KRAS
fail to respond to anti-EGFR therapy and display
inferior outcomes when therapy is combined with
oxaliplatin-based chemotherapy.1–5 It is also appar-
ent that a signiﬁcant proportion of exon 2 wild-
type (WT) patients gain no beneﬁt from anti-EGFR
therapy. This has led to the need for additional
reﬁnement of the patient population receiving such
therapy, in order to better select patients for
treatment, and equally identify those who will gain
no beneﬁt from a toxic drug regimen.
Recently available data, resulting primarily from
the reanalysis of several large randomised controlled
trials (RCTs), have provided evidence for the intro-
duction of an extended RAS testing panel, to include
NRAS testing and also to cover signiﬁcantly more
mutation hotspots, in KRAS. A prospective–retro-
spective analysis was carried out on the phase III
PRIME study6 to evaluate the treatment effect of
panitumumab-FOLFOX4 (Pan-FOLFOX4), when
compared with FOLFOX4 alone, in patients with
RAS-WT (KRAS and NRAS exons 2, 3 and 4 WT)
and patients with RAS-WT plus BRAF-WT (KRAS
and NRAS exons 2, 3 and 4 and BRAF exon 15
WT). Both overall survival (OS) and progression-
free survival (PFS) were signiﬁcantly increased with
Pan-FOLFOX4. Furthermore, 17% of the 639
patients with mCRC, with no KRAS mutation in
exon 2, had additional RAS mutations, which were
associated with worse PFS and OS, when treated
with Pan-FOLFOX4.
Last year, data were published from the phase III
CRYSTAL trial7 where extended RAS testing was
carried out on the mCRC KRAS exon 2 WT trial
population. As was seen in the PRIME study, both
OS and PFS were signiﬁcantly increased in the
patients receiving cetuximab plus FOLFIRI, com-
pared with those receiving FOLFIRI alone. The
percentage of patients who carried RAS mutations
in addition to KRAS exon 2 was 14.7%, which is
similar to the level identiﬁed in the patients in the
PRIME trial (17%).
The data from these two large trials, in combin-
ation with the data from a further 13 articles,8–19
formed the basis of the recent American Society of
Clinical Oncology (ASCO) Provisional Clinical
Opinion (PCO) update.20 The recommendation of
the PCO was that KRAS exon 2 (codons 12 and 13)
mutations should be assessed in addition to KRAS
exon 3 (codons 59 and 61) and exon 4 (codons
117 and 146), along with NRAS exon 2 (codons 12
and 13), exon 3 (codons 59 and 61) and exon 4
(codons 117 and 146).
Current European guidelines for prescribing
anti-EGFR monoclonal antibody therapy (http://
www.ema.europa.eu/docs/en_GB/document_library/
Summary_of_opinion/human/000741/WC5001448
27.pdf) state that ‘Vectibix (Panitumumab) is indi-
cated for the treatment of adult patients with wild-
type RAS metastatic colorectal cancer (mCRC)’,
without speciﬁcally stating which codons must be
tested. In the UK, however, the Association of
Clinical Pathologists Molecular Pathology and
Diagnostics Group devised a set of guidelines, direc-
ted at UK practice and more speciﬁcally within the
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National Health Service (NHS).21 The recommendation was that
RAS testing for treatment with anti-EGFR therapies should
include, as a minimum, KRAS codons 12, 13, 59, 61, 117 and 146
and NRAS codons 12, 13, 59 and 61. As these codons account for
over 99% of RAS-activating mutations,22 UK National External
Quality Assessment Service (UK NEQAS) for Molecular Genetics
has provided assessment of molecular testing of colorectal cancer
since 200823 and has determined that it is good practice for all of
these to be covered by laboratories participating in their External
Quality Assessment (EQA) schemes.
Given that there is now adequate data available conﬁrming
the need to perform extended RAS testing, we report here on
the very varied range of RAS (KRAS and NRAS) codons being
routinely tested for mutation detection, across four UK NEQAS
for Molecular Genetics Colorectal cancer EQA schemes, with
laboratory testing being performed between October 2014 and
November 2015, in up to 110 UK and international
laboratories.
MATERIALS AND METHODS
The UK NEQAS for Molecular Genetics EQA scheme for the
molecular genetic analysis of colorectal cancer is provided twice
during each 12-month period, with approximately 6 months
between each run. Multiple formalin-ﬁxed, parafﬁn-embedded
(FFPE) colorectal tumour tissue blocks were sourced to include
a number of WT and RAS mutations, and variable sample pro-
cessing/ﬁxation processes into the scheme. To ensure the
samples distributed for the EQA scheme gave reportable accur-
ate RAS results, each sample was tested in two independent, val-
idating laboratories using two different testing methods, prior to
being sent out to participating laboratories. Consent was in
place to allow the use of this excess pathological material in the
UK NEQAS EQA scheme. Data were available from the two
runs delivered in 2014–2015 (Runs 1 and 2) and the two runs
delivered during 2015–2016 (Runs 1 and 2). Each year, partici-
pating laboratories are sent samples with ﬁve ﬁctitious clinical
scenarios in Run 1 and four in Run 2. Laboratories are expected
to test these nine samples in accordance with local laboratory
practice and report results for both KRAS and NRAS testing. It
was deemed optional as to whether laboratories chose to report
BRAF and PIK3CA testing results. Each laboratory was required
to stipulate the preferred sample type: rolled sections for each
case; rolled sections plus a slide-mounted section or only slide-
mounted sections, and all requests were met by UK NEQAS. An
estimate of tumour percentage was expected from each labora-
tory, for each tumour sample, or a statement indicating that
tumour assessment was not carried out. None of the tumour
samples distributed had less than 20% tumour cell content.
Each laboratory was also required to provide a clinical interpret-
ation of their results according to the clinical cases provided,
and state the methodologies used for mutation detection.
RESULTS
Scheme participation
Eighty-six laboratories registered to participate in Run 1 of the
2014–2015 scheme, and of these, 84 submitted results.
Ninety-one laboratories registered to participate in Run 2, and
again 84 submitted results. In the 2015–2016 scheme, 101
laboratories registered to participate in Run 1, and 99 submitted
results, and 108/120 registered laboratories returned results in
Run 2. The two laboratories in Run 1 and six laboratories in
Run 2 failing to submit reports in the 2014–2015 scheme fol-
lowed the correct protocol, and contacted the Scheme to advise
them of the non-submission of results. Likewise, the two
laboratories in Run 1 and seven laboratories in Run 2 failing to
report results for the 2015–2016 scheme also followed the
correct protocol. However, one laboratory in Run 2 of the
2014–2015 scheme and ﬁve laboratories in Run 2 of the 2015–
2016 scheme were deemed poor performing laboratories due to
non-submission in accordance with the published guidelines.
Sample type tested
The distribution of sample types requested did not vary much
across the four schemes. Table 1 shows the percentage of labora-
tories requesting mounted FFPE tumour sections only, rolled
sections of tissue plus a slide-mounted section or rolled sections
only.
Regions of KRAS and NRAS tested
A comparison of the regions of KRAS and NRAS covered by
mutation screening across the three schemes was performed. For
KRAS, there was an increase in the number of laboratories
testing each codon, with the largest increases seen in codons 59,
117 and 146. There was also an increase in the number of
laboratories stating just the exons tested (exons 2, 3 and 4), indi-
cative of an increase in the number of laboratories moving to a
next generation sequencing (NGS) platform (table 2). For
NRAS, a very similar pattern was seen across all codons;
however, clearly, there are still fewer laboratories testing NRAS,
although a smaller proportion of participating laboratories is
failing to report results for NRAS (table 3).
Table 1 Distribution of sample types requested by the
laboratories, registering for each of the four schemes
Run 1
2014–15
(n=86)
Run 2
2014–15
(n=91)
Run 1
2015–16
(n=101)
Run 2
2015–16
(n=120)
Mounted FFPE
section only
34 (40%) 34 (37%) 37 (37%) 46 (38%)
Rolled section plus
mounted FFPE
section
36 (42%) 40 (44%) 46 (46%) 53 (44%)
Rolled section only 16 (19%) 17 (19%) 18 (18%) 21 (18%)
For each run, not every laboratory requesting material went on to complete their
submission
FFPE, formalin-fixed, paraffin-embedded.
Table 2 Percentage of laboratories in each scheme run, stating
the codons (or exons) that were covered in their screening panels
for KRAS
Codons or
exons tested
KRAS Run 1
(2014–15)
n=84
KRAS Run 2
(2014–15)
n=84
KRAS Run 1
(2015–16)
n=99
KRAS Run 2
(2015–16)
n=108
Codons 12/13 82.1 89.3 81.8 76.9
Codon 59 14.3 15.5 20.2 29.6
Codon 61 73.8 85.5 71.7 69.4
Codon 117 16.7 41.6 47.5 50.9
Codon 146 35.7 52.4 54.5 54.6
Exon 2 9.5 9.5 12.1 15.7
Exon 3 9.5 9.5 12.1 15.7
Exon 4 4.8 4.8 10.1 13.9
Not specified 8.3 1.2 6.1 7.4
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We investigated the gene regions tested in the most recent
scheme (Runs 1 and 2 of 2015–2016), which was provided fol-
lowing the updated UK guidelines.21 Each laboratory was
expected to state which regions of KRAS and NRAS were
covered by their screening protocol. Despite this requirement,
ﬁve laboratories in Run 1 and eight laboratories in Run 2 failed
to provide this information on their diagnostic clinical report.
There was a slight decrease in the percentage of laboratories
not testing for mutations in NRAS, dropping from 12/99
(12.1%) to 11/108 (10.2%) from Run 1 to Run 2. In Run 1,
there were two samples harbouring NRAS mutations: one con-
taining a c.35G>T and one containing a c.181C>A mutation.
In Run 2, there was one sample harbouring a c.34 G>T muta-
tion. Thus, 12 and 11 laboratories failed to report these muta-
tions in Runs 1 and 2, respectively.
Tables 4 and 5 show the proportion of laboratories meeting,
or failing to meet, the UK and US guidelines for extended RAS
testing respectively. Despite the increase seen across the two
runs, there was still a signiﬁcant proportion of laboratories that
was effectively undertesting.
Taking into account the current UK NEQAS for Molecular
Genetics recommendations, only 24/99 (24.2%) and 39/108
(36.1%) of laboratories are meeting these minimum require-
ments in Runs 1 and 2, respectively.
When the current ASCO guidelines are taken into account,
only 19/99 (19.2%) of laboratories met the recommendations in
Run 1, with this rising to 26/108 (24.1%) in Run 2.
DISCUSSION
In an era of personalised medicine, it is becoming increasingly
important to identify which patients will respond to speciﬁc
drugs, and equally, which will gain no beneﬁt. Furthermore,
additional stratiﬁcation is required to ensure the greatest beneﬁts
are obtained, once patients are selected for individual treatment.
It was established in 2008 that KRAS mutation was a negative
predictive biomarker of response to panitumumab3 and cetuxi-
mab.1 24 In these studies, only KRAS codons 12 and 13 were
tested for the presence of pathogenic mutations. The PICCOLO
trial, run across the UK, was one of the ﬁrst mCRC randomised
trials to introduce prospective mutation testing, allowing ran-
domisation based on mutation status.25 Again, only KRAS status,
at codons 12, 13 and 61, was assessed prospectively. Based on
the evidence of the low response rate to anti-EGFR therapies,
the group also carried out a retrospective analysis of additional
mutation hotspots (BRAF codon 600; NRAS codons 12, 13 and
61; KRAS codon 146; PIK3CA codons 542, 545-6 and 1047).
Patients who were WTat all loci (‘all wild-type’) demonstrated a
high response rate to panitumumab (70/160 (44%)) and also an
improved PFS (HR 0.68; 95% CI 0.53 to 0.86), whereas
patients whose tumours contained any mutation demonstrated a
detrimental effect from panitumumab, in terms of PFS (HR
1.20; 95% CI 0.83 to 1.74). During 2015, there was a publica-
tion of the extended RAS testing retrospectively carried out on
patients in the OPUS trial.26 Only 26% of the 118 evaluable
patients were found to harbour an additional RAS mutation.
Patients with WT tumours demonstrated an improved objective
response with the addition of cetuximab to FOLFOX4 (58% vs
29%; OR 3.3, 95% CI 1.36 to 8.7; p=0.0084), whereas those
with any mutation derived no beneﬁt, and indeed demonstrated
a detrimental effect. These data, in combination with the
extended RAS testing in CRYSTAL and PRIME, have highlighted
the need for extended mutation testing, particularly where there
is the potential of a detrimental effect on the patient.
Laboratories proving a clinical service in terms of RAS muta-
tion screening should be participating in a regular EQA scheme,
to ensure adequate quality measures are met. The UK NEQAS
Table 3 Percentage of laboratories in each scheme run, stating
the codons (or exons) that were covered in their screening panels
for NRAS
Codons or
exons tested
NRAS Run
1 (2014–15)
n=84
NRAS Run
2 (2014–15)
n=84
NRAS Run
1 (2015–16)
n=99
NRAS Run 2
(2015–16)
n=108
Codons 12/13 58.3 73.8 68.7 66.7
Codon 59 14.3 22.6 23.2 28.7
Codon 61 71.4 73.8 65.7 63.9
Codon 117 15.5 20.2 21.2 21.3
Codon 146 21.4 26.2 30.3 29.6
Exon 2 10.7 10.7 13.1 15.7
Exon 3 10.7 10.7 13.1 15.7
Exon 4 6 16.7 10.1 11.1
Not tested 22.6 13.1 12.1 10.2
Not specified 8.3 1.2 6.1 7.4
Table 4 The percentages of laboratories either meeting the UK
guidelines for extended RAS testing, or indeed overtesting or
undertesting
Run 1
(n=99)
Run 2
(n=108)
Percentage of laboratories exactly following UK
guidelines
6.1 25.9
Percentage of laboratories overtesting 19.2 10.2
Percentage of laboratories undertesting 68.7 55.6
Percentage of laboratories where the testing panel
was undetermined
6 8.3
TOTAL percentage of laboratories testing at least in
accordance with UK guidelines
25.3 36.1
Adding together the laboratories following the UK guidelines and those overtesting
gives the total percentage of laboratories meeting or exceeding the minimum
requirements. The UK guidelines suggest the following coverage: KRAS codons 12,
13, 59, 61, 117 and 146 in addition to NRAS codons 12, 13, 59 and 61.
Table 5 The percentages of laboratories either meeting the US
guidelines for extended RAS testing, or indeed overtesting or
undertesting
Run 1
(n=99)
Run 2
(n=108)
Percentage of laboratories exactly following ASCO
guidelines
4 13
Percentage of laboratories overtesting 15.2 11.1
Percentage of laboratories undertesting 74.8 67.6
Percentage of laboratories where the testing panel
was undetermined
6 8.3
TOTAL percentage of laboratories testing at least in
accordance with ASCO guidelines
19.6 24.1
Adding together the laboratories following the US guidelines and those overtesting
gives the total percentage of laboratories meeting or exceeding the minimum
requirements. The current American Society of Clinical Oncology (ASCO) guidelines
state that the coverage should include KRAS exon 2 (codons 12 and 13), KRAS exon
3 (codons 59 and 61), KRAS exon 4 (codons 117 and 146), in addition to NRAS exon
2 (codons 12 and 13), NRAS exon 3 (codons 59 and 61) and NRAS exon 4 (codons
117 and 146).
60 Richman SD, et al. J Clin Pathol 2017;70:58–62. doi:10.1136/jclinpath-2016-203822
Original article
group.bmj.com on January 25, 2017 - Published by http://jcp.bmj.com/Downloaded from 
for Molecular Genetics Colorectal cancer EQA scheme has
observed an increase in the number of laboratories participating
and in the breadth of codons screened by participants over the
course of the past four EQA runs (October 2014 to November
2015). It was noted that not all laboratories carry out a path-
ology review of each tumour sample. Almost 20% of participat-
ing laboratories requested rolled sections only for testing, and
were thus unable to assess the tumour content, as requested in
the scheme. These laboratories were not penalised, providing an
indication was given on the laboratory report, that this was the
case. UK NEQAS would rather assess each laboratory’s routine
process; so, if they do not routinely assess tumour content, yet
report clinical results, it is preferable that this is assessed by the
EQA provider, rather than routine processing be amended for
scheme participation. Most markedly have been increases in the
number of laboratories now including KRAS codons 59, 117
and 146 in their screening panels. Furthermore, there has been
a substantial increase in the number of laboratories including
NRAS testing into the testing strategies. Increased implementa-
tion of NGS panel testing was seen across the four runs exam-
ined. In Run 1 of 2014–2015, only 9.5% of laboratories were
using NGS to screen for mutations on KRAS, and 11.9% were
using NGS to screen NRAS. This increased to 23.1% in Run 2
of 2015–2016, for both KRAS and NRAS. It was observed that
the format of reporting NGS results was highly variable, and
many reports did not state the gene panel or sequencing plat-
form used. As this is not a scheme requirement, laboratories
were not penalised for failing to provide this information. The
implementation of gene panel testing is clearly becoming more
routine practice, as testing requirements increase. This will
become more challenging as the demand for large-panel gene
mutation screening on small, diagnostic biopsies, where the lim-
iting factor will be the tissue sample itself, increases.
As previously mentioned, in both USA and UK, there are now
published guidelines on extended RAS testing.20 21 Alarmingly, we
have shown here that of the laboratories (n=108) participating in
the most recent EQA scheme, only 24.1% of laboratories met the
ASCO guidelines and 36.1% met the UK guidelines. Figures
based on the CRYSTAL and PRIME6 7 studies would suggest
that although 40% of patients with mCRC are likely to have a
KRAS exon 2 mutation, there are still between 14.7% and 17% of
patients with an additional RAS mutation, providing strong
evidence for extended RAS testing. In the USA, there are currently
two FDA-approved mutation screening kits (Therascreen RGD
PCR kit and the Roche cobas KRAS mutation testing kit), both of
which only cover seen mutations in codons 12 and 13 of KRAS.
These kits are clearly a very long way from meeting the ASCO
guidelines, yet may have to be used in certain laboratories. In
Europe, the European Medicines Agency (EMA) is not prescriptive
as to the testing methodologies or scope of testing, which enables
laboratories to introduce in-house developed tests or other commer-
cially available kits, which incorporate wider RAS testing. Each
laboratory therefore has the choice of determining the extent of
testing in accordance with best-practice guidance. However, the
implementation of new tests requires validation and veriﬁcation,
which are costly, and many testing centres have no resources for
such validation. This may go some way to explaining the limited
and different testing strategies employed across the scheme
participants. Clearly, there is still a long way to go before these
guidelines are followed in routine practice, and until this happens,
we will see a larger than necessary patient cohort, subjected to the
detrimental effects of their anti-EGFR therapies, which would not
have been prescribed, had an extended RAS panel been incorpo-
rated into practice.
Take home messages
▸ We have provided evidence of the nature of current RAS
testing, across 100 global laboratories, in the context of an
international quality assurance scheme.
▸ We have demonstrated the alarming lack of full extended
RAS testing, in accordance to both UK and US guidelines.
▸ Practice must be altered to bring laboratories in line with
these evidence-based guidelines to ultimately provide a high
standard of patient care.
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